Syndicated Research Studies

The global liquid biopsy market was valued at USD 10.42 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 11.60% from 2024 to 2030. The market's growth is primarily driven by several key factors, including the rising prevalence of cancer worldwide, continuous technological advancements in cancer diagnostics, and an increasing preference for minimally invasive diagnostic methods for cancer detection. Additionally, ongoing research into liquid biopsy assays and tests, along with the growing adoption and development of multi-cancer early detection tests, is expected to create further opportunities for market expansion. The COVID-19 pandemic had a significant impact on cancer diagnoses, leading to delays in diagnostic services and screening programs due to restrictions and overburdened healthcare systems. Cancer patients also faced numerous challenges during this period, including increased vulnerability to severe infections and disruptions in their...

Liquid Biopsy Market Size & Trends The global liquid biopsy market size was estimated at USD 10.42 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 11.60% from 2024 to 2030. The market for liquid biopsy is witnessing growth due to factors such as the growing prevalence of cancer, technological advancements in cancer diagnostics, and rising preference for minimally invasive cancer diagnostics. Moreover, ongoing research for liquid biopsy assays and tests, aided with the rising adoption and development of multi-cancer early detection tests,  provides opportunity for growth of overall market. With the onset of COVID-19 pandemic, cancer diagnoses were delayed due to reduced diagnostic services and screening programs. Cancer patients are facing many challenges amid the pandemic, such as susceptibility to severe infection and interruption of cancer or usual medical care. The negative impact is likely to be stronger in low- and middle-income count...

Liquid Biopsy Market Growth & Trends The global  Liquid Biopsy Market  size was valued at USD 22.88 billion in 2030 and is expected to expand at a compound annual growth rate (CAGR) of 9.7% from 2023 to 2030. The increasing prevalence of cancer and the growing geriatric population are major drivers expected to fuel market growth. Furthermore, the use of technologically advanced devices for early detection of diseases is one of the key factors driving the market. In addition, the increasing preference for noninvasive treatment procedures will offer lucrative opportunities in the forecast period. In recent years, cases of cancer have been rising tremendously and the trend is projected to remain the same in the foreseeable future. A significant shift in lifestyle has exposed the global population to this disorder and has resulted in oncogenic factors. For instance, as per the American Cancer Society, in 2022, the number of new cancer cases is expected to reach 1.9 million, ...

Liquid Biopsy Industry Overview The global  liquid biopsy market  size is expected to reach USD 19.35 billion by 2028, registering a CAGR of 13.5% during the forecast period, according to a new report by Grand View Research, Inc. It is a revolutionary technique that has created various opportunities that were previously unexplored. Liquid Biopsy Market Segmentation Grand View Research has segmented the global liquid biopsy market on the basis of sample type, biomarker, technology, and region: Based on the Sample Type Insights, the market is segmented into Blood Sample Based and Others. Blood sample-based tests dominated the market with a revenue share of over 69%. A blood-based test is non-invasive, has no risk, and is painless. In addition, it reduces the cost and time taken for diagnosis. CTCs, cfDNAs, and exosomes, as well as microvesicles, can be detected in the blood sample, thus increasing the adoption of blood-based liquid biopsy. The circulating  biomarker...